Présentation de l'entreprise
Repare Therapeutics Inc. operates as a clinical-stage precision oncology entity focused on the discovery and development of novel therapeutics within both Switzerland and the United States. The company leverages its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to identify and advance cancer therapies designed to treat specific genetic drivers of the disease. This biotechnology firm functions within the broader healthcare sector, specifically navigating the highly competitive and capital-intensive biotechnology industry where research and development are central to value creation. As of the latest reporting period, the company holds a market capitalization of $114.24M, generates annual revenue of $11.87M, and employs 129 individuals across its operational locations. The relatively modest market cap combined with the lack of reported revenue growth suggests the company remains in an early-stage development phase, where valuation is driven primarily by pipeline potential and intellectual property rather than current cash flow generation.
Santé financière
Repare Therapeutics reported revenue of $11.87M over the trailing twelve months, yet this top-line figure masks a significant operational deficit with a net income of -$72,200,000 and an EBITDA of -$76,462,000. The substantial gap between positive revenue and deeply negative net income reveals a cost structure characterized by high research and development expenditures typical of clinical-stage biotechnology firms, where costs far exceed current sales. The company generated free cash flow of -$42,824,248, indicating that its current financial flexibility is constrained by heavy burn rates that require external capital to sustain operations. Despite the negative earnings, the company maintains a robust liquidity position with $112.60M in cash on hand against a negligible debt level of $342,000. The analysis of margins shows a gross margin of 403.4%, an operating margin of -3.7%, and a profit margin of 0.0%, illustrating that while the cost of goods sold is low relative to sales, overhead costs severely erode profitability. The balance sheet appears conservative given the massive cash reserve compared to the minimal debt, resulting in a debt-to-equity ratio of 0.30. Short-term liquidity is exceptionally strong with a current ratio of 10.71, providing ample coverage for immediate obligations. Finally, the return on equity stands at -49.8% and return on assets at -29.7%, metrics that reflect the reality of an unprofitable company where management has not yet achieved capital efficiency or positive shareholder returns.
Évaluation de la valorisation
Valuation metrics for Repare Therapeutics present a complex picture, with a trailing P/E ratio listed as N/A and a forward P/E of -0.89, implying that future earnings are also projected to be negative or that the market is pricing in a return to profitability that has not yet materialized. The price-to-book ratio is 0.99, indicating that the stock trades at approximately book value, which suggests the market does not currently assign a significant premium to the company's intangible assets or future pipeline potential. Alternative valuation multiples provide further insight, with a price-to-sales ratio of 9.62 and an EV/EBITDA of -0.02, suggesting the market values the company based on revenue generation rather than earnings power. The stock's trading range over the past year has seen a 52-week high of $2.66 and a 52-week low of $0.89, with the current price situated within this volatility band. The beta value of 0.96 indicates that the stock's price volatility moves in line with the broader market, offering no significant defensive or aggressive characteristics relative to the overall index.
Growth & Income
The company reports N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, reflecting the absence of comparable prior periods or consistent historical data typical for emerging clinical-stage entities. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which is sustainable given the current losses and aligns with the strategy of reinvesting all available resources into research and development rather than shareholder distributions. This approach confirms that the company prioritizes growth initiatives, such as advancing its oncology pipeline, over income generation for investors. Consequently, the overall growth and income profile is defined by a lack of current earnings expansion and a complete absence of dividend income, relying entirely on the successful execution of its therapeutic discovery platform to drive future value creation.